West Pharmaceutical Services, Inc. (NYSE:WST) Stock Holdings Reduced by Kintegral Advisory LLC

Kintegral Advisory LLC reduced its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 60.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,377 shares of the medical instruments supplier’s stock after selling 6,736 shares during the period. Kintegral Advisory LLC’s holdings in West Pharmaceutical Services were worth $1,442,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in WST. Evoke Wealth LLC bought a new position in West Pharmaceutical Services in the 4th quarter worth approximately $7,770,000. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in West Pharmaceutical Services by 1.5% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 191,469 shares of the medical instruments supplier’s stock valued at $75,766,000 after purchasing an additional 2,759 shares during the last quarter. Vanguard Group Inc. increased its holdings in West Pharmaceutical Services by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 9,002,632 shares of the medical instruments supplier’s stock valued at $3,170,007,000 after purchasing an additional 104,740 shares in the last quarter. Mizuho Markets Americas LLC lifted its position in West Pharmaceutical Services by 142.3% during the 1st quarter. Mizuho Markets Americas LLC now owns 29,628 shares of the medical instruments supplier’s stock worth $11,724,000 after buying an additional 17,399 shares in the last quarter. Finally, Hsbc Holdings PLC raised its position in West Pharmaceutical Services by 39.8% in the 4th quarter. Hsbc Holdings PLC now owns 138,468 shares of the medical instruments supplier’s stock worth $48,750,000 after purchasing an additional 39,392 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $297.61 on Thursday. The stock has a market capitalization of $21.59 billion, a price-to-earnings ratio of 39.26, a PEG ratio of 10.79 and a beta of 1.00. West Pharmaceutical Services, Inc. has a 52 week low of $265.00 and a 52 week high of $415.73. The firm has a fifty day moving average of $310.34 and a two-hundred day moving average of $344.67. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.68 and a current ratio of 2.34.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). The firm had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period in the prior year, the business earned $2.11 EPS. As a group, equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.44 EPS for the current year.

Insider Activity

In other West Pharmaceutical Services news, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total transaction of $595,404.00. Following the transaction, the senior vice president now owns 2,860 shares in the company, valued at approximately $946,030.80. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the transaction, the vice president now owns 1,478 shares of the company’s stock, valued at $443,400. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Silji Abraham sold 1,800 shares of the company’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now directly owns 2,860 shares in the company, valued at $946,030.80. The disclosure for this sale can be found here. 0.53% of the stock is owned by company insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.